Toggle navigation
Login
Toggle navigation
JavaScript is disabled for your browser. Some features of this site may not work without it.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
QMRO Home
Barts Cancer Institute
Centre for Molecular Oncology
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
QMRO Home
Barts Cancer Institute
Centre for Molecular Oncology
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Browse
All of QMRO
Communities & Collections
By Issue Date
Authors
Titles
Subjects
This Collection
By Issue Date
Authors
Titles
Subjects
Administrators only
Login
Statistics
Most Popular Items
Statistics by Country
Most Popular Authors
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Volume
380
Pagination
1116 - 1127
DOI
10.1056/NEJMoa1816714
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Issue
12
ISSN
0028-4793
Metadata
Show full item record
Authors
Rini, BI; Plimack, ER; Stus, V; Gafanov, R; Hawkins, R; Nosov, D; Pouliot, F; Alekseev, B; Soulieres, D; Melichar, B
URI
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65839
Collections
Centre for Molecular Oncology
[272]